Zavegepant hydrochloride

• CAT Number: I048000
• CAS Number: 1414976-20-7
• Molecular Formula: C36H47ClN8O3
• Molecular Weight: 675.3
• Purity: 98%
• Synonyms: BHV-3500 hydrochloride; Vazegepant HCl
• Target: CGRP
• Target Protein: VQDUWCSSPSOSNA-RYWNGCACSA-N
• Appearance: Solid
• IUPAC Name: N-[(2R)-3-(7-methyl-1H-indazol-5-yl)-1-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-1-oxopropan-2-yl]-4-(2-oxo-1H-quinolin-3-yl)piperidine-1-carboxamide;hydrochloride
• InChI: InChI=1S/C36H46N8O3.ClH/c1-24-19-25(20-28-23-37-40-33(24)28)21-32(35(46)43-17-15-42(16-18-43)29-9-11-41(2)12-10-29)39-36(47)44-13-7-26(8-14-44)30-22-27-5-3-4-6-31(27)38-34(30)45;/h3-6,19-20,22-23,26,29,32H,7-18,21H2,1-2H3,(H,37,40)(H,38,45)(H,39,47);1H/t32-;/m1./s1
• SMILES: CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O.Cl

Zavegepant hydrochloride (CAS 1414976-20-7) is a pharmaceutical compound with potential therapeutic applications in the treatment of migraine headaches. As a calcitonin gene-related peptide (CGRP) receptor antagonist, Zavegepant acts by inhibiting the binding of CGRP to its receptor, which is implicated in the pathophysiology of migraines. By blocking this interaction, Zavegepant aims to alleviate migraine symptoms. Ongoing research and clinical trials are exploring its effectiveness and safety profile, offering hope for an innovative and targeted approach to managing this prevalent neurological condition.